Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystitis, Interstitial | 20 | 2020 | 45 | 5.300 |
Why?
|
| Urinary Bladder | 6 | 2019 | 182 | 1.380 |
Why?
|
| Pelvic Pain | 4 | 2017 | 18 | 1.010 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 64 | 0.650 |
Why?
|
| Anesthesia | 1 | 2019 | 64 | 0.650 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 54 | 0.580 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 232 | 0.500 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2012 | 9 | 0.420 |
Why?
|
| Sacrum | 1 | 2012 | 22 | 0.420 |
Why?
|
| Administration, Intravesical | 5 | 2020 | 24 | 0.390 |
Why?
|
| Pain | 1 | 2013 | 287 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 407 | 0.370 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2010 | 16 | 0.360 |
Why?
|
| Retrospective Studies | 7 | 2020 | 3505 | 0.350 |
Why?
|
| Humans | 23 | 2020 | 32082 | 0.340 |
Why?
|
| Diagnostic Errors | 2 | 2007 | 43 | 0.330 |
Why?
|
| Middle Aged | 12 | 2020 | 11834 | 0.320 |
Why?
|
| Urinary Bladder Diseases | 2 | 2020 | 21 | 0.310 |
Why?
|
| Female | 14 | 2020 | 19999 | 0.300 |
Why?
|
| Adult | 11 | 2020 | 9375 | 0.290 |
Why?
|
| Urinary Incontinence | 1 | 2005 | 47 | 0.250 |
Why?
|
| Pentosan Sulfuric Polyester | 4 | 2008 | 4 | 0.220 |
Why?
|
| Aged | 8 | 2019 | 10308 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 516 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3990 | 0.170 |
Why?
|
| Polyneuropathies | 1 | 2019 | 10 | 0.170 |
Why?
|
| Water | 1 | 2019 | 56 | 0.170 |
Why?
|
| Endometriosis | 1 | 2020 | 99 | 0.170 |
Why?
|
| Adolescent | 5 | 2019 | 3568 | 0.160 |
Why?
|
| Fibromyalgia | 1 | 2019 | 25 | 0.160 |
Why?
|
| Urinary Diversion | 1 | 2017 | 26 | 0.150 |
Why?
|
| RNA | 2 | 2016 | 92 | 0.140 |
Why?
|
| Compliance | 1 | 2017 | 13 | 0.140 |
Why?
|
| Male | 8 | 2019 | 19202 | 0.140 |
Why?
|
| Syndrome | 2 | 2014 | 72 | 0.140 |
Why?
|
| Cystectomy | 1 | 2017 | 105 | 0.140 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2020 | 2282 | 0.140 |
Why?
|
| Organ Size | 1 | 2017 | 218 | 0.140 |
Why?
|
| Urine | 1 | 2017 | 65 | 0.140 |
Why?
|
| Algorithms | 2 | 2010 | 496 | 0.130 |
Why?
|
| Lumbosacral Plexus | 2 | 2012 | 5 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 337 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 72 | 0.120 |
Why?
|
| Young Adult | 2 | 2019 | 2665 | 0.120 |
Why?
|
| Instillation, Drug | 1 | 2013 | 2 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3304 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1542 | 0.110 |
Why?
|
| North Carolina | 1 | 2017 | 1538 | 0.110 |
Why?
|
| Risk Factors | 2 | 2020 | 3880 | 0.110 |
Why?
|
| Cystoscopy | 2 | 2014 | 27 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 493 | 0.100 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2007 | 4 | 0.070 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2007 | 10 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 15 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2007 | 37 | 0.070 |
Why?
|
| Physical Examination | 1 | 2007 | 92 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 240 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2006 | 27 | 0.070 |
Why?
|
| Mandelic Acids | 1 | 2005 | 2 | 0.070 |
Why?
|
| Efferent Pathways | 1 | 2005 | 8 | 0.070 |
Why?
|
| Afferent Pathways | 1 | 2005 | 23 | 0.070 |
Why?
|
| Muscarinic Antagonists | 1 | 2005 | 14 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 632 | 0.060 |
Why?
|
| Prostatitis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Neurotoxins | 1 | 2005 | 16 | 0.060 |
Why?
|
| Diterpenes | 1 | 2005 | 19 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2008 | 525 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 753 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2016 | 547 | 0.060 |
Why?
|
| Animals | 1 | 2013 | 7510 | 0.050 |
Why?
|
| Cations | 1 | 2020 | 10 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 102 | 0.040 |
Why?
|
| Anesthetics | 1 | 2019 | 18 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2014 | 406 | 0.040 |
Why?
|
| Cadaver | 1 | 2016 | 161 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 294 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2263 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 14 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 19 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 259 | 0.030 |
Why?
|
| Glycosylation | 1 | 2011 | 15 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 989 | 0.020 |
Why?
|
| Heparinoids | 1 | 2007 | 1 | 0.020 |
Why?
|
| Hydroxyzine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Amitriptyline | 1 | 2007 | 6 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2007 | 20 | 0.020 |
Why?
|
| Solutions | 1 | 2007 | 36 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2007 | 12 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 14 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2007 | 38 | 0.020 |
Why?
|
| Heparin | 1 | 2007 | 73 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 187 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 629 | 0.020 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 78 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 288 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2007 | 80 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 560 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 240 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 63 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 53 | 0.020 |
Why?
|
| Diarrhea | 1 | 2005 | 60 | 0.020 |
Why?
|
| Headache | 1 | 2005 | 75 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2005 | 349 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 881 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 946 | 0.010 |
Why?
|